Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Radioactive polymeric nanoparticles for biomedical application

S. Wu, E. Helal-Neto, APDS. Matos, A. Jafari, J. Kozempel, YJA. Silva, C. Serrano-Larrea, S. Alves Junior, E. Ricci-Junior, F. Alexis, R. Santos-Oliveira

. 2020 ; 27 (1) : 1544-1561. [pub] -

Language English Country Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21026368

Nowadays, emerging radiolabeled nanosystems are revolutionizing medicine in terms of diagnostics, treatment, and theranostics. These radionuclides include polymeric nanoparticles (NPs), liposomal carriers, dendrimers, magnetic iron oxide NPs, silica NPs, carbon nanotubes, and inorganic metal-based nanoformulations. Between these nano-platforms, polymeric NPs have gained attention in the biomedical field due to their excellent properties, such as their surface to mass ratio, quantum properties, biodegradability, low toxicity, and ability to absorb and carry other molecules. In addition, NPs are capable of carrying high payloads of radionuclides which can be used for diagnostic, treatment, and theranostics depending on the radioactive material linked. The radiolabeling process of nanoparticles can be performed by direct or indirect labeling process. In both cases, the most appropriate must be selected in order to keep the targeting properties as preserved as possible. In addition, radionuclide therapy has the advantage of delivering a highly concentrated absorbed dose to the targeted tissue while sparing the surrounding healthy tissues. Said another way, radioactive polymeric NPs represent a promising prospect in the treatment and diagnostics of cardiovascular diseases such as cardiac ischemia, infectious diseases such as tuberculosis, and other type of cancer cells or tumors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026368
003      
CZ-PrNML
005      
20211026132946.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/10717544.2020.1837296 $2 doi
035    __
$a (PubMed)33118416
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Wu, Shentian $u Department of Radiotherapy Center, Maoming People's Hospital, Maoming City, China
245    10
$a Radioactive polymeric nanoparticles for biomedical application / $c S. Wu, E. Helal-Neto, APDS. Matos, A. Jafari, J. Kozempel, YJA. Silva, C. Serrano-Larrea, S. Alves Junior, E. Ricci-Junior, F. Alexis, R. Santos-Oliveira
520    9_
$a Nowadays, emerging radiolabeled nanosystems are revolutionizing medicine in terms of diagnostics, treatment, and theranostics. These radionuclides include polymeric nanoparticles (NPs), liposomal carriers, dendrimers, magnetic iron oxide NPs, silica NPs, carbon nanotubes, and inorganic metal-based nanoformulations. Between these nano-platforms, polymeric NPs have gained attention in the biomedical field due to their excellent properties, such as their surface to mass ratio, quantum properties, biodegradability, low toxicity, and ability to absorb and carry other molecules. In addition, NPs are capable of carrying high payloads of radionuclides which can be used for diagnostic, treatment, and theranostics depending on the radioactive material linked. The radiolabeling process of nanoparticles can be performed by direct or indirect labeling process. In both cases, the most appropriate must be selected in order to keep the targeting properties as preserved as possible. In addition, radionuclide therapy has the advantage of delivering a highly concentrated absorbed dose to the targeted tissue while sparing the surrounding healthy tissues. Said another way, radioactive polymeric NPs represent a promising prospect in the treatment and diagnostics of cardiovascular diseases such as cardiac ischemia, infectious diseases such as tuberculosis, and other type of cancer cells or tumors.
650    _2
$a zvířata $7 D000818
650    _2
$a nosiče léků $x chemie $7 D004337
650    _2
$a lékové transportní systémy $x metody $7 D016503
650    _2
$a lidé $7 D006801
650    _2
$a nanočástice $x chemie $7 D053758
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a polymery $x chemie $7 D011108
650    _2
$a radionuklidy $x aplikace a dávkování $x chemie $7 D011868
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Helal-Neto, Edward $u Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro, Brazil
700    1_
$a Matos, Ana Paula Dos Santos $u Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
700    1_
$a Jafari, Amir $u Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro, Brazil $u Department of Medical Nanotechnology in the Faculty of Advanced Technology in Medicine, Iran University of Medical Science, Tehran, Iran
700    1_
$a Kozempel, Ján $u Faculty of Nuclear Sciences and Physical Engineering (FJFI), Czech Technical University in Prague (ČVUT), Prague, Czech Republic
700    1_
$a Silva, Yuri José de Albuquerque $u Department of Fundamental Chemistry, Federal University of Pernambuco, Recife, Brazil
700    1_
$a Serrano-Larrea, Carolina $u School of Biological Sciences and Engineering, Yachay Tech University, Urcuquí, Ecuador
700    1_
$a Alves Junior, Severino $u Department of Fundamental Chemistry, Federal University of Pernambuco, Recife, Brazil
700    1_
$a Ricci-Junior, Eduardo $u Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
700    1_
$a Alexis, Frank $u School of Biological Sciences and Engineering, Yachay Tech University, Urcuquí, Ecuador
700    1_
$a Santos-Oliveira, Ralph $u Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro, Brazil $u Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, Zona Oeste State University, Rio de Janeiro, Brazil
773    0_
$w MED00006308 $t Drug delivery $x 1521-0464 $g Roč. 27, č. 1 (2020), s. 1544-1561
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33118416 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132952 $b ABA008
999    __
$a ok $b bmc $g 1715168 $s 1146875
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 27 $c 1 $d 1544-1561 $e - $i 1521-0464 $m Drug delivery $n Drug Deliv $x MED00006308
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options